SAN FRANCISCO, May 11, 2026--Ciridae, the AI transformation firm building operating systems for real economy businesses, today announced it has raised $20 million in seed funding led by Accel, with participation from Andreessen Horowitz, General Catalyst, Sunflower Capital, and Backcountry Ventures. Founded by CEO Jack Soslow, former partner at Andreessen Horowitz and data scientist at Meta, and C...
SAN FRANCISCO, May 11, 2026--Ciridae, the AI transformation firm building operating systems for real economy businesses, today announced it has raised $20 million in seed funding led by Accel, with participation from Andreessen Horowitz, General Catalyst, Sunflower Capital, and Backcountry Ventures. Founded by CEO Jack Soslow, former partner at Andreessen Horowitz and data scientist at Meta, and CTO Jack Weissenberger, former engineering team leader at Salesforce and Head of ML at Teneyx, Cirida
Reply will participate in SAP Sapphire & ASUG Annual Conference Orlando 2026 (May 11–13), showcasing its expertise in delivering and implementing SAP Business Suite solutions, including SAP Cloud ERP (Public and Private), SAP Business Data Cloud (BDC), SAP Business Technology Platform (BTP), and AI-powered enterprise capabilities. Reply's presence at SAP Sapphire underscores its strategic partners...
Reply will participate in SAP Sapphire & ASUG Annual Conference Orlando 2026 (May 11–13), showcasing its expertise in delivering and implementing SAP Business Suite solutions, including SAP Cloud ERP (Public and Private), SAP Business Data Cloud (BDC), SAP Business Technology Platform (BTP), and AI-powered enterprise capabilities. Reply's presence at SAP Sapphire underscores its strategic partnership with SAP and its commitment to delivering SAP-led, AI-driven transformation for its clients.
After a brief correction and subsequent rebound, NuScale Power (NYSE: SMR) -- a popular nuclear energy stock -- currently has a market cap of just $4.3 billion. If shares rose in value by 1,000%, the company's market cap would still be somewhere around $43 billion. While there is plenty of execution risk, this magnitude of upside potential is clearly possible given the market estimates discussed b...
After a brief correction and subsequent rebound, NuScale Power (NYSE: SMR) -- a popular nuclear energy stock -- currently has a market cap of just $4.3 billion. If shares rose in value by 1,000%, the company's market cap would still be somewhere around $43 billion. While there is plenty of execution risk, this magnitude of upside potential is clearly possible given the market estimates discussed below. According to analysts from Goldman Sachs , nuclear energy is now "a key area of focus globally as countries revisit the technology after many years of underinvestment." Increased investment in nuclear energy technology is already on the rise. "Global investment in nuclear power generation grew at a compound annual growth rate of 14% between 2020 and 2024, following almost five years of no growth in spending," a recent Goldman Sachs report concluded. NuScale, of course, isn't betting on nuclear power in general. The company specifically designs small modular reactors, or SMRs. These are essentially miniature nuclear power plants, making them faster, easier, and cheaper to construct. Continue reading
Matthew Charles Brown, Chief Financial Officer of Tenable (NASDAQ:TENB) , reported the open-market purchase of 12,000 shares at around $21.54 per share on May 4, 2026, according to a SEC Form 4 filing . Transaction and post-transaction values based on SEC Form 4 weighted average purchase price ($21.54). * 1-year price change calculated using May 4, 2026 as the reference date. Continue reading
Matthew Charles Brown, Chief Financial Officer of Tenable (NASDAQ:TENB) , reported the open-market purchase of 12,000 shares at around $21.54 per share on May 4, 2026, according to a SEC Form 4 filing . Transaction and post-transaction values based on SEC Form 4 weighted average purchase price ($21.54). * 1-year price change calculated using May 4, 2026 as the reference date. Continue reading
Tatiana rico/iStock via Getty Images Brookfield Asset Management ( BAM ) is set to invest $500M in The OpenAI Deployment Company, an AI deployment platform established in partnership with OpenAI and a group of 19 investors. The partnership is led by TPG ( TPG ), with Advent, Bain Capital, and Brookfield as co-lead founding partners; and B Capital, BBVA ( BBVA ), Emergence Capital, Goanna, Goldman ...
Tatiana rico/iStock via Getty Images Brookfield Asset Management ( BAM ) is set to invest $500M in The OpenAI Deployment Company, an AI deployment platform established in partnership with OpenAI and a group of 19 investors. The partnership is led by TPG ( TPG ), with Advent, Bain Capital, and Brookfield as co-lead founding partners; and B Capital, BBVA ( BBVA ), Emergence Capital, Goanna, Goldman Sachs ( GS ), SoftBank Corp. ( SOBKY ), Warburg Pincus, and WCAS as founding partners. Investors also include Bain & Company, Capgemini ( CAPMF ) ( CGEMY ), and McKinsey & Company. OpenAI ( OPENAI ) today announced the launch of the platform in a separate release. In connection with the launch, OpenAI has agreed to acquire the applied AI consulting and engineering firm Tomoro. The acquisition is expected to bring ~150 experienced forward-deployed engineers and deployment specialists to the platform. The platform enables large enterprises to move from pilot AI use cases to scaled, enterprise-wide deployment. "AI is becoming capable of doing increasingly meaningful work inside organizations. The challenge now is helping companies integrate these systems into the infrastructure and workflows that power their businesses," said OpenAI's chief revenue officer, Denise Dresser. BAM's investment will be led by Brookfield Business Corporation ( BBUC ), a flagship listed vehicle of the company's private equity business. Additionally, Brookfield expects to draw on The OpenAI Deployment Company's capabilities across its operating companies and investment platform to accelerate productivity initiatives, improve decision-making, and drive efficiency gains. "Artificial intelligence will be a defining driver of productivity across the backbone of the global economy," said Anuj Ranjan, CEO of Brookfield's private equity business. "We are pleased to partner with OpenAI to support the development of a platform that combines their leading AI technology with Brookfield's operating expertise to d...
The former England keeper has the chance to represent his country once again after flourishing as a senior cricketer “I once hit a six in very murky conditions to win a game which got us promoted.” Nigel Martyn is lost in a reverie. The former England, Leeds, Everton and Crystal Palace player was English football’s first £1m goalkeeper, chalked up 846 club appearances in a career that spanned thre...
The former England keeper has the chance to represent his country once again after flourishing as a senior cricketer “I once hit a six in very murky conditions to win a game which got us promoted.” Nigel Martyn is lost in a reverie. The former England, Leeds, Everton and Crystal Palace player was English football’s first £1m goalkeeper, chalked up 846 club appearances in a career that spanned three decades, went to two World Cups and played in an FA Cup final. But it is a smear over long-on in the Yorkshire gloaming that has him misty-eyed. “Wow. I remember that feeling was … yeah. That was as good as any feeling that I had on a football field.” Continue reading...
Fokusiert/iStock via Getty Images Investment Overview - FDA Commissioner Marty Makary On The Brink A couple of weeks ago, I covered the news that Replimmune ( REPL ), a Massachusetts-based biotech, had had its Biologics License Application ("BLA") requesting approval for its lead drug candidate RP1 (vusolimogene oderparepvec) in combination with nivolumab for the treatment of adult patients with a...
Fokusiert/iStock via Getty Images Investment Overview - FDA Commissioner Marty Makary On The Brink A couple of weeks ago, I covered the news that Replimmune ( REPL ), a Massachusetts-based biotech, had had its Biologics License Application ("BLA") requesting approval for its lead drug candidate RP1 (vusolimogene oderparepvec) in combination with nivolumab for the treatment of adult patients with advanced melanoma rejected for the second time. Just a few days ago, I also covered the Q1 earnings of Iovance Biotherapeutics ( IOVA ), whose tumor-infiltrating lymphocyte ("TIL") therapy Amtagvi (lifileucel) was approved to treat advanced melanoma in in 2024 - Amtagvi earned revenues of $60m, and is forecast to earn ~$80m in Q2, up >20% over Q4 2025. I awarded Replimmune stock a Sell rating, and Iovance a Buy rating. The two companies' market caps are respectively $336m (although Replimmune stock is up >20% pre-market) and ~$1.6bn, yet in a parallel universe, it could have been Replimmune's therapy on the market, earning hundreds of millions of dollars per annum, and Iovance shareholders scratching their heads and wondering on what grounds the Food & Drug Administration ("FDA") had denied lifileucel approval. These are the kinds of marginal decisions that the FDA makes on an almost daily basis. However it is beginning to seem likely that the decision not to approve RP1, amongst others, could cost the FDA Commissioner Dr. Marty Makary his job. President Trump has reportedly signed off on the firing of Dr. Makary, the Wall Street Journal has suggested, potentially putting an end to a turbulent reign, involving a seemingly non-stop series of controversies, although when asked about the matter by journalists last week, the President told reporters "I've been reading about it...I know nothing about it." The controversies Dr. Makary has become embroiled in have been well documented - for example, a lack of decisive action on the restriction of the abortion drug, mifepristone, th...
Keir Starmer says ‘agitators’ will be blocked from attending Tommy Robinson’s Unite the Kingdom event Seven people hoping to attend a far-right rally in central London on Saturday have been blocked from entering the country by the home secretary, Shabana Mahmood. Keir Starmer, the prime minister, promised on Monday to block “far-right agitators” hoping to attend the Unite the Kingdom event on 16 M...
Keir Starmer says ‘agitators’ will be blocked from attending Tommy Robinson’s Unite the Kingdom event Seven people hoping to attend a far-right rally in central London on Saturday have been blocked from entering the country by the home secretary, Shabana Mahmood. Keir Starmer, the prime minister, promised on Monday to block “far-right agitators” hoping to attend the Unite the Kingdom event on 16 May organised by Tommy Robinson, whose real name is Stephen Yaxley-Lennon. Continue reading...
Brighton festival Combining words devised for Shakespeare’s female characters with music from composers old and new this was a Bardic treat with teeth The two groups behind me who (it emerged at the interval) were all expecting a greatest hits concert by 90s pop duo Shakespears Sister , might have been startled by what they got instead: a Shakespeare-themed song recital. But you can hardly move fo...
Brighton festival Combining words devised for Shakespeare’s female characters with music from composers old and new this was a Bardic treat with teeth The two groups behind me who (it emerged at the interval) were all expecting a greatest hits concert by 90s pop duo Shakespears Sister , might have been startled by what they got instead: a Shakespeare-themed song recital. But you can hardly move for lovers and their lasses hey-nonny-no-ing their way across the UK’s concert halls these days, and it takes something extra to set one apart. Sophie Bevan and pianist Christopher Glynn found it by combining Shakespeare with speeches from actor Harriet Walter’s 2024 book She Speaks! Walter’s wry, often acerbic, occasionally dagger-wielding verse fills in the gaps where women – whether witches, wives, nurses or ingenues – should speak, but don’t. Paired with a brilliantly unexpected selection of Shakespeare songs, many by female composers, it made for more than a simply pretty recital. Continue reading...